focus -WSS

focus

author：comprehensive 2025-10-01 23:01:56 - browse：3

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Senate panel passes drug pricing bills, but drops one PBM reform

WSS

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Timeline: Key moments in fight for gay rights

Emergency workers more likely to restrain Black patients: study

Emergency workers more likely to restrain Black patients: study

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Second xenotransplant done with gene

hotspot

focus

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA panel to weigh approval of NurOwn, controversial ALS drug

Cancer drug shortages should be causing more outrage

What Congress can do to address the rural doctor shortage

Heart attack and stroke risk calculators need revising

It's been 20 years since Dolly the sheep. Where's my clone?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Eli Lilly’s Mounjaro succeeds in second weight

Hollywood unions extend contract negotiations for actors

Second xenotransplant done with gene

focus

CommonSpirit Health keeps growing, even as it loses money

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Second xenotransplant done with gene

Eli Lilly’s Mounjaro succeeds in second weight

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Biotech lab space demand falls sharply

entertainment

focus

focus

leisure time